Forskning ved Københavns Universitet - Københavns Universitet

Forside

Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade : An exploratory study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade  : An exploratory study. / Düring, Signe W.; Nielsen, Mette; Bak, Nikolaj; Glenthøj, Birte Y.; Ebdrup, Bjørn H.

I: Psychiatry Research, Bind 274, 04.2019, s. 58-65.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Düring, SW, Nielsen, M, Bak, N, Glenthøj, BY & Ebdrup, BH 2019, 'Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade : An exploratory study', Psychiatry Research, bind 274, s. 58-65. https://doi.org/10.1016/j.psychres.2019.02.017

APA

Düring, S. W., Nielsen, M., Bak, N., Glenthøj, B. Y., & Ebdrup, B. H. (2019). Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade : An exploratory study. Psychiatry Research, 274, 58-65. https://doi.org/10.1016/j.psychres.2019.02.017

Vancouver

Düring SW, Nielsen M, Bak N, Glenthøj BY, Ebdrup BH. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade : An exploratory study. Psychiatry Research. 2019 apr;274:58-65. https://doi.org/10.1016/j.psychres.2019.02.017

Author

Düring, Signe W. ; Nielsen, Mette ; Bak, Nikolaj ; Glenthøj, Birte Y. ; Ebdrup, Bjørn H. / Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade  : An exploratory study. I: Psychiatry Research. 2019 ; Bind 274. s. 58-65.

Bibtex

@article{a921023072e245c187c08b5e998f24dc,
title = "Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade : An exploratory study",
abstract = " Sexual side-effects along with antipsychotic treatment may be linked to hyperprolactinemia and dopamine D 2 receptor blockade. High prevalence of sexual dysfunction in un-medicated patients challenges the notion of sexual dysfunction as merely a side-effect of antipsychotic medication. Sexual dysfunction was assessed in fifty-six initially antipsychotic-na{\"i}ve patients with schizophrenia using the UKU (Udvalget for Kliniske Unders{\o}gelser) questionnaire. Serum-prolactin was obtained before and after six weeks of D 2/3 receptor blockade with amisulpride. At baseline 68% of patients reported one or more items of sexual dysfunction (males > females,), but the cumulative load of sexual dysfunction was similar in males and females. After 6 weeks treatment with amisulpride (mean dose 279 mg/day), 65% of patients reported one or more items of sexual dysfunctions (females > males). There was a significant sex*time interaction on mean sexual dysfunction load. All patients developed hyperprolactinaemia, and a significant effect of time and sex was found on s-prolactin (females > males). The results support that patients with schizophrenia report high levels of sexual dysfunction before antipsychotic exposure. After treatment, sexual side-effects were more frequent in females, coinciding with pronounced serum-prolactin increases. These findings suggest sex differences in sexual dysfunction before and after antipsychotic treatment. ",
keywords = "Antipsychotics, First episode schizophrenia, Hyperprolactinaemia, Sexual side-effects",
author = "D{\"u}ring, {Signe W.} and Mette Nielsen and Nikolaj Bak and Glenth{\o}j, {Birte Y.} and Ebdrup, {Bj{\o}rn H.}",
year = "2019",
month = apr,
doi = "10.1016/j.psychres.2019.02.017",
language = "English",
volume = "274",
pages = "58--65",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D2/3 receptor blockade 

T2 - An exploratory study

AU - Düring, Signe W.

AU - Nielsen, Mette

AU - Bak, Nikolaj

AU - Glenthøj, Birte Y.

AU - Ebdrup, Bjørn H.

PY - 2019/4

Y1 - 2019/4

N2 - Sexual side-effects along with antipsychotic treatment may be linked to hyperprolactinemia and dopamine D 2 receptor blockade. High prevalence of sexual dysfunction in un-medicated patients challenges the notion of sexual dysfunction as merely a side-effect of antipsychotic medication. Sexual dysfunction was assessed in fifty-six initially antipsychotic-naïve patients with schizophrenia using the UKU (Udvalget for Kliniske Undersøgelser) questionnaire. Serum-prolactin was obtained before and after six weeks of D 2/3 receptor blockade with amisulpride. At baseline 68% of patients reported one or more items of sexual dysfunction (males > females,), but the cumulative load of sexual dysfunction was similar in males and females. After 6 weeks treatment with amisulpride (mean dose 279 mg/day), 65% of patients reported one or more items of sexual dysfunctions (females > males). There was a significant sex*time interaction on mean sexual dysfunction load. All patients developed hyperprolactinaemia, and a significant effect of time and sex was found on s-prolactin (females > males). The results support that patients with schizophrenia report high levels of sexual dysfunction before antipsychotic exposure. After treatment, sexual side-effects were more frequent in females, coinciding with pronounced serum-prolactin increases. These findings suggest sex differences in sexual dysfunction before and after antipsychotic treatment.

AB - Sexual side-effects along with antipsychotic treatment may be linked to hyperprolactinemia and dopamine D 2 receptor blockade. High prevalence of sexual dysfunction in un-medicated patients challenges the notion of sexual dysfunction as merely a side-effect of antipsychotic medication. Sexual dysfunction was assessed in fifty-six initially antipsychotic-naïve patients with schizophrenia using the UKU (Udvalget for Kliniske Undersøgelser) questionnaire. Serum-prolactin was obtained before and after six weeks of D 2/3 receptor blockade with amisulpride. At baseline 68% of patients reported one or more items of sexual dysfunction (males > females,), but the cumulative load of sexual dysfunction was similar in males and females. After 6 weeks treatment with amisulpride (mean dose 279 mg/day), 65% of patients reported one or more items of sexual dysfunctions (females > males). There was a significant sex*time interaction on mean sexual dysfunction load. All patients developed hyperprolactinaemia, and a significant effect of time and sex was found on s-prolactin (females > males). The results support that patients with schizophrenia report high levels of sexual dysfunction before antipsychotic exposure. After treatment, sexual side-effects were more frequent in females, coinciding with pronounced serum-prolactin increases. These findings suggest sex differences in sexual dysfunction before and after antipsychotic treatment.

KW - Antipsychotics

KW - First episode schizophrenia

KW - Hyperprolactinaemia

KW - Sexual side-effects

UR - http://www.scopus.com/inward/record.url?scp=85061549124&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2019.02.017

DO - 10.1016/j.psychres.2019.02.017

M3 - Journal article

C2 - 30780063

AN - SCOPUS:85061549124

VL - 274

SP - 58

EP - 65

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

ER -

ID: 239560797